This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluatethe safety and efficacy of MK-2870 plus paclitaxel versus Ramucirumab plus paclitaxel,for the treatment of participants with advanced or metastatic gastric adenocarcinoma,gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who havefailed 1 prior line of therapy. This is an estimation study, and no formal hypothesistesting will be performed.
This is a phase 1/2 multicenter, open-label umbrella platform study that will evaluatethe safety and efficacy of MK-2870 plus paclitaxel versus Ramucirumab plus paclitaxel,for the treatment of participants with advanced or metastatic gastric adenocarcinoma,gastroesophageal junction (GEJ) adenocarcinoma, or esophageal adenocarcinoma who havefailed 1 prior line of therapy. This is an estimation study, and no formal hypothesistesting will be performed.
